Cargando…

Clinical Use of a 180-Day Implantable Glucose Monitoring System in Dogs with Diabetes Mellitus: A Case Series

SIMPLE SUMMARY: A novel continuous glucose monitoring system (CGMS) equipped with a long-term sensor has recently been developed for humans with diabetes mellitus. The sensor is inserted under the skin and continuously measures the glucose in the interstitial fluid over a period of up to 180 days. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Tardo, Antonio Maria, Irace, Concetta, Del Baldo, Francesca, Foglia, Armando, Fracassi, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996934/
https://www.ncbi.nlm.nih.gov/pubmed/35405848
http://dx.doi.org/10.3390/ani12070860
_version_ 1784684588309676032
author Tardo, Antonio Maria
Irace, Concetta
Del Baldo, Francesca
Foglia, Armando
Fracassi, Federico
author_facet Tardo, Antonio Maria
Irace, Concetta
Del Baldo, Francesca
Foglia, Armando
Fracassi, Federico
author_sort Tardo, Antonio Maria
collection PubMed
description SIMPLE SUMMARY: A novel continuous glucose monitoring system (CGMS) equipped with a long-term sensor has recently been developed for humans with diabetes mellitus. The sensor is inserted under the skin and continuously measures the glucose in the interstitial fluid over a period of up to 180 days. The aim of this study was to describe, for the first time, the clinical use of this novel CGMS in three diabetic dogs (DD). The insertion and use of the device were straightforward and well tolerated by the dogs. Some device-related issues, such as sensor dislocation and trouble with daily calibrations, were reported. A good correlation between the glucose values measured by this CGMS and those obtained with a flash glucose monitoring system and a portable-blood glucose meter, previously validated for use in DD, was found (rs = 0.85 and rs = 0.81, respectively). The functional life of the sensor was 180 days in two of the three dogs, and the use of the device provided high satisfaction to the owners. This innovative device might be considered a future alternative for continuous glucose monitoring in dogs with diabetes mellitus. ABSTRACT: The novel Eversense XL continuous glucose monitoring system (Senseonics, Inc., Germantown, Maryland) has recently been developed for monitoring diabetes in humans. The sensor is fully implanted and has a functional life of up to 180 days. The present study describes the use of Eversense XL in three diabetic dogs (DD) with good glycemic control managed by motivated owners. The insertion and use of the device were straightforward and well tolerated by the dogs. During the wearing period, some device-related drawbacks, such as sensor dislocation and daily calibrations, were reported. A good correlation between the glucose values measured by the Eversense XL and those obtained with two commercially available devices, previously validated for use in DD, was found (r(s) = 0.85 and r(s) = 0.81, respectively). The life of the sensor was 180 days in two of the DD and provided high satisfaction. This innovative device might be considered a future alternative for home glucose monitoring in DD.
format Online
Article
Text
id pubmed-8996934
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89969342022-04-12 Clinical Use of a 180-Day Implantable Glucose Monitoring System in Dogs with Diabetes Mellitus: A Case Series Tardo, Antonio Maria Irace, Concetta Del Baldo, Francesca Foglia, Armando Fracassi, Federico Animals (Basel) Case Report SIMPLE SUMMARY: A novel continuous glucose monitoring system (CGMS) equipped with a long-term sensor has recently been developed for humans with diabetes mellitus. The sensor is inserted under the skin and continuously measures the glucose in the interstitial fluid over a period of up to 180 days. The aim of this study was to describe, for the first time, the clinical use of this novel CGMS in three diabetic dogs (DD). The insertion and use of the device were straightforward and well tolerated by the dogs. Some device-related issues, such as sensor dislocation and trouble with daily calibrations, were reported. A good correlation between the glucose values measured by this CGMS and those obtained with a flash glucose monitoring system and a portable-blood glucose meter, previously validated for use in DD, was found (rs = 0.85 and rs = 0.81, respectively). The functional life of the sensor was 180 days in two of the three dogs, and the use of the device provided high satisfaction to the owners. This innovative device might be considered a future alternative for continuous glucose monitoring in dogs with diabetes mellitus. ABSTRACT: The novel Eversense XL continuous glucose monitoring system (Senseonics, Inc., Germantown, Maryland) has recently been developed for monitoring diabetes in humans. The sensor is fully implanted and has a functional life of up to 180 days. The present study describes the use of Eversense XL in three diabetic dogs (DD) with good glycemic control managed by motivated owners. The insertion and use of the device were straightforward and well tolerated by the dogs. During the wearing period, some device-related drawbacks, such as sensor dislocation and daily calibrations, were reported. A good correlation between the glucose values measured by the Eversense XL and those obtained with two commercially available devices, previously validated for use in DD, was found (r(s) = 0.85 and r(s) = 0.81, respectively). The life of the sensor was 180 days in two of the DD and provided high satisfaction. This innovative device might be considered a future alternative for home glucose monitoring in DD. MDPI 2022-03-29 /pmc/articles/PMC8996934/ /pubmed/35405848 http://dx.doi.org/10.3390/ani12070860 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Tardo, Antonio Maria
Irace, Concetta
Del Baldo, Francesca
Foglia, Armando
Fracassi, Federico
Clinical Use of a 180-Day Implantable Glucose Monitoring System in Dogs with Diabetes Mellitus: A Case Series
title Clinical Use of a 180-Day Implantable Glucose Monitoring System in Dogs with Diabetes Mellitus: A Case Series
title_full Clinical Use of a 180-Day Implantable Glucose Monitoring System in Dogs with Diabetes Mellitus: A Case Series
title_fullStr Clinical Use of a 180-Day Implantable Glucose Monitoring System in Dogs with Diabetes Mellitus: A Case Series
title_full_unstemmed Clinical Use of a 180-Day Implantable Glucose Monitoring System in Dogs with Diabetes Mellitus: A Case Series
title_short Clinical Use of a 180-Day Implantable Glucose Monitoring System in Dogs with Diabetes Mellitus: A Case Series
title_sort clinical use of a 180-day implantable glucose monitoring system in dogs with diabetes mellitus: a case series
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996934/
https://www.ncbi.nlm.nih.gov/pubmed/35405848
http://dx.doi.org/10.3390/ani12070860
work_keys_str_mv AT tardoantoniomaria clinicaluseofa180dayimplantableglucosemonitoringsystemindogswithdiabetesmellitusacaseseries
AT iraceconcetta clinicaluseofa180dayimplantableglucosemonitoringsystemindogswithdiabetesmellitusacaseseries
AT delbaldofrancesca clinicaluseofa180dayimplantableglucosemonitoringsystemindogswithdiabetesmellitusacaseseries
AT fogliaarmando clinicaluseofa180dayimplantableglucosemonitoringsystemindogswithdiabetesmellitusacaseseries
AT fracassifederico clinicaluseofa180dayimplantableglucosemonitoringsystemindogswithdiabetesmellitusacaseseries